Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
O95391
UPID:
SLU7_HUMAN
Alternative names:
-
Alternative UPACC:
O95391; D3DQK2; Q3LUJ0; Q3LUJ1; Q6RXQ5; Q96FM9
Background:
Pre-mRNA-splicing factor SLU7 plays a pivotal role in pre-mRNA splicing, a critical step in gene expression. It is essential for the spliceosome's second catalytic step, ensuring accurate mRNA splicing and intron excision. SLU7's specificity in holding exon 1 and identifying the correct AG in 3'-splicing sites underscores its importance in the splicing process and alternative splicing regulation.
Therapeutic significance:
Understanding the role of Pre-mRNA-splicing factor SLU7 could open doors to potential therapeutic strategies. Its critical function in mRNA processing highlights its potential as a target in diseases where splicing errors contribute to pathogenesis.